Novartis FDA approves Rhapsido for symptomatic dermographism

Basel, October 7, 2026 — Novartis announced today that the U.S. Food and Drug Administration (FDA) approved Rhapsido® (remibrutinib), an oral, highly selective Bruton’s tyrosine kinase inhibitor (BTKi), as the first treatment for adults with symptomatic dermographism (SD) inadequately controlled by…

Novartis said the FDA approved Rhapsido (remibrutinib) as the first treatment for adults with symptomatic dermographism inadequately controlled by H1 antihistamines, expanding its use beyond chronic spontaneous urticaria.Material DetailsContext by AI AnalystThis is a mid-cycle expansion of remibrut…